Clusterin is a biomarker of breast cancer prognosis and correlated with immune microenvironment

Background It has been established that clusterin is involved in the invasion of immune cells in the tumor microenvironment, but it remains unknown how it promotes immune invasion in breast cancer. Methods We used Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA) databases to assess the relation between expression of clusterin and immunoinfiltration-related marker genes. TIMER database was used to evaluate the expression of clusterin, and its relation to tumor immune invasion was examined. Based on Kaplan-Meier plotter database, we investigated the association between clusterin expression and prognosis in patients with cancer, and the impact of clinicopathological factors and cancer-related outcomes. Results Clusterin expression was markedly associated with prognosis of a variety of tumors, specifically breast cancer. Enhanced clusterin expression was markedly associated with molecular typing of breast cancer and expression of multiple markers related to specific immune cell subsets. Conclusions These results indicate that clusterin is connected to prognosis of breast cancer patients and tumor immune cell infiltration. This demonstrates that clusterin may be a biomarker of immune cell recruitment into breast tumors and an important biomarker for immune cell infiltration; consequently being a valuable prognostic factor in breast cancer patients.

[1]  H. Eguchi,et al.  Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer , 2022, Annals of Surgical Oncology.

[2]  Yisheng Fan,et al.  The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer , 2022, Cancer management and research.

[3]  V. Hoyos,et al.  Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1 , 2021, Biomedicines.

[4]  S. Shekhar,et al.  In silico structural analysis of secretory clusterin to assess pathogenicity of mutations identified in the evolutionarily conserved regions , 2021, Journal of biomolecular structure & dynamics.

[5]  M. Burkard,et al.  Breast cancer immunotherapy: current biomarkers and the potential of in vitro assays. , 2021, Current opinion in biomedical engineering.

[6]  A. Schneeweiss,et al.  First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Y. Wang,et al.  Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Su Yang,et al.  The multiple roles and therapeutic potential of clusterin in non-small-cell lung cancer: a narrative review , 2021, Translational lung cancer research.

[9]  Xiu-Li Wang,et al.  miR-217-5p Inhibits Invasion and Metastasis of Prostate Cancer by Targeting Clusterin , 2021, Mammalian Genome.

[10]  N. Chuaypen,et al.  The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma , 2021, Scientific Reports.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  Xinxing Ma,et al.  Inhibition Lysosomal Degradation of Clusterin by Protein Kinase D3 Promotes Triple‐Negative Breast Cancer Tumor Growth , 2021, Advanced science.

[13]  S. Patra,et al.  Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[14]  Ahn， Jin Hee,et al.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.

[15]  C. González-Martín,et al.  Clusterin: Always protecting. Synthesis, function and potential issues. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  Y. Nan,et al.  Clusterin contributes to hepatitis C virus-related hepatocellular carcinoma by regulating autophagy. , 2020, Life sciences.

[17]  Shuohua Chen,et al.  Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1 , 2019, Journal of Cell Science.

[18]  K. Maruyama,et al.  Development of Dendritic Cell-Based Immunotherapy Targeting Tumor Blood Vessels in a Mouse Model of Lung Metastasis. , 2019, Biological & pharmaceutical bulletin.

[19]  Mei Peng,et al.  The role of Clusterin in cancer metastasis , 2019, Cancer management and research.

[20]  Weiliang Gao,et al.  sCLU as prognostic biomarker and therapeutic target in osteosarcoma , 2019, Bioengineered.

[21]  S. Chae,et al.  The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer , 2018, BMC Cancer.

[22]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[23]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[24]  A. Lánczky,et al.  miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.

[25]  R. Boidot,et al.  Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients , 2016, Oncoimmunology.

[26]  Daniel Birnbaum,et al.  Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2–JNK signalling in breast cancer , 2016, Nature Communications.

[27]  F. R. Lenicov,et al.  Fucosylated clusterin in semen promotes the uptake of stress-damaged proteins by dendritic cells via DC-SIGN. , 2015, Human reproduction.

[28]  M. A. Afanasyeva,et al.  Clusterin Is a Potential Lymphotoxin Beta Receptor Target That Is Upregulated and Accumulates in Germinal Centers of Mouse Spleen during Immune Response , 2014, PloS one.

[29]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[30]  B. Chun,et al.  Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. , 2013, European review for medical and pharmacological sciences.

[31]  Hui Zhao,et al.  Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression , 2012, Journal of chemotherapy.

[32]  Kenta Nakai,et al.  PrognoScan: a new database for meta-analysis of the prognostic value of genes , 2009, BMC Medical Genomics.

[33]  yang-xin fu,et al.  NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. , 2006, Blood.

[34]  M. Gleave,et al.  Antisense clusterin oligodeoxynucleotides increase the response of HER‐2 gene amplified breast cancer cells to Trastuzumab , 2005, Journal of cellular physiology.